| |
High blood pressure occurs in approximately 40% of PKD patients by the time they are in their twenties and is associated with increased kidney size and left heart size, which can lead to congestive heart disease. To avoid cardiovascular complications, it is important for ADPKD patients to maintain their blood pressure within a normal range. Learn More About PKD & Heart Disease
Blood Pressure Regulation Clinical Trials
|
HALT PKD Progression of PKD (HALT PKD)
|
Intervention:
|
Drugs - lisonopril, telmisartan |
|
Sponsor:
|
University of Pittsburgh Medical Center |
Study Phase:
|
III |
| Status: |
Active; enrollment complete |
|
Enrollment goal:
|
1,018 |
|
Description:
|
To assess the effectiveness of anti-hypertensive drugs telmisartan and lisinopril on PKD progression and its cardiovascular complications in two different levels of kidney function, GFR more than 60 mL/min/1/73m^2 and GFR between 25-60 mL/min/1.73m^2. |
| Additional Information: |
The Data Collection Center is now located at the University of Pittsburgh Medical Center. |
| Contact: |
|
| Website: |
NIH Study Details |
|
|
Effect of Statin Therapy on Disease Progression in ADPKD
|
Intervention:
|
Drug - Pravastatin |
|
Sponsor:
|
University of Colorado at Denver and Health Sciences Center |
|
Study Phase:
|
III |
| Status: |
Recruiting |
| Age Group: |
8-21 |
|
Enrollment goal:
|
100 |
|
Description:
|
To determine the effect of pravastatin treatment on renal and cardiovascular disease over a 3-year study period in children and young adults aged 8-21 years with ADPKD. |
| Contact: |
Melissa Cadnapaphornchai, M.D. at 303-724-1690 or pkd.nurse@uchsc.edu
Linda Perkins at 303-724-1690 or pkd.nurse@uchsc.edu.
You may also call toll-free at 1-877-765-9297.
|
| Website: |
NIH Study Details
|
|
|
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in ADPKD
|
Intervention:
|
Drug - High or low sodium diet |
|
Sponsor:
|
Holstebro Hospital, Denmark |
| Status: |
Recruiting |
| Age Group: |
18-65 |
|
Enrollment goal:
|
25 |
|
Description:
|
To examine the effect of high and low diets on kidney function and on hormones that affect the kidney. |
| Contact: |
Carolina Cannillo, M.D. at 1145099125428 or cacan@ringamt.dk |
| Website: |
NIH Study Details |
|
|
CCB Safety Study in Treatment of Hypertension in ADPKD
|
Intervention:
|
Drugs - Candesartan; Candesartan Cilnidipine; Candesartan non-calcium channel blocker (CCB) |
|
Sponsor:
|
Kyorin University, Japan |
|
Study Phase:
|
IV |
| Status: |
Recruiting |
| Age Group: |
20-60 |
|
Enrollment goal:
|
150 |
|
Description:
|
To evaluate the safety and efficacy of calcium channel blocker Candesartan in treatment of hypertension in ADPKD patients. |
| Contact: |
Eiji Higashihara, M.D. at 81-422-47-5511, ext. 5813 or ehigashi@kyorin-u.ac.jp |
| Website: |
NIH Study Details |
|
|
Study for the Second Line Treatment of Hypertension in Patients With ADPKD
|
Intervention:
|
Drug - Candesartan, Cilnidipine, Imidapril |
|
Sponsor:
|
The Ministry of Health, Labour & Welfare, Japan; Teikyo University |
|
Study Phase:
|
II |
| Status: |
Not yet Recruiting |
| Age Group: |
20-60 |
|
Enrollment goal:
|
160 |
|
Description:
|
To compare the safety and effectiveness of combination therapy to control blood pressure in patients with ADPKD whose blood pressure is not controlled under 120/80 with ARB alone. Either ACE or CCB will be added to the regimen and results will be compared to those on ARB alone.
ARB – angiotensin receptor blocker ACE – angiotensin converting enzyme inhibitor CCB – Calcium channel blocker
|
| Contact: |
Shigeo Horie, MD at +81339642497shorie@med.teikyo-u.ac.jp
Satoru Muto, MD, PhD at +81339642497muto@med.teiku-u.ac.jp |
| Website: |
NIH Study Details
|
|
|
|